V. Peddareddigari

发表

Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial.

K. Flaherty, R. Kurzrock, N. Le, 2012, The Lancet. Oncology.

Activity of the MEK Inhibitor Trametinib (GSK1120212) in Advanced Melanoma in a Phase I, Dose-escalation Trial

K. Flaherty, R. Kurzrock, N. Le, 2014 .

Oral MEK1/MEK2 inhibitor trametinib (GSK1120212) in combination with docetaxel in KRAS-mutant and wild-type (WT) advanced non-small cell lung cancer (NSCLC): A phase I/Ib trial.

Keunchil Park, D. Gandara, J. Infante, 2013 .

Phase 1 study of JNJ-42756493, a pan-fibroblast growth factor receptor (FGFR) inhibitor, in patients with advanced solid tumors.

J. Tabernero, J. Soria, R. Dienstmann, 2014 .

NUT midline carcinoma: an aggressive intrathoracic neoplasm.

B. Costello, R. Marks, G. Shapiro, 2013, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Phase I clinical and pharmacologic study of the focal adhesion kinase (FAK) inhibitor GSK2256098 in pts with advanced solid tumors.

R. Plummer, M. Ranson, J. Soria, 2012 .

Abstract CT325: First in human study of JNJ-42756493, a potent pan fibroblast growth factor receptor (FGFR) inhibitor in patients with advanced solid tumors

J. Tabernero, C. Takimoto, J. Soria, 2014 .

ACCELERATE and European Medicines Agency Paediatric Strategy Forum for medicinal product development of checkpoint inhibitors for use in combination therapy in paediatric patients.

A. Jenkner, K. Norga, Martha Donoghue, 2020, European journal of cancer.

Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial.

K. Flaherty, R. Kurzrock, L. Hart, 2012, The Lancet. Oncology.

The Tumor Microenvironment in Colorectal Carcinogenesis

R. DuBois, D. Wang, V. Peddareddigari, 2010, Cancer Microenvironment.

Phase I Dose-Escalation Study of JNJ-42756493, an Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients With Advanced Solid Tumors.

J. Tabernero, A. Italiano, J. Soria, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A Phase 1/1b Study Evaluating Trametinib Plus Docetaxel or Pemetrexed in Patients With Advanced Non–Small Cell Lung Cancer

K. Kelly, D. Gandara, F. Shepherd, 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

A phase I, pharmacokinetic and pharmacodynamic study of GSK2256098, a focal adhesion kinase inhibitor, in patients with advanced solid tumors.

R. Plummer, M. Ranson, J. Soria, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

Clinical activity of the oral MEK1/MEK2 inhibitor GSK1120212 in pancreatic and colorectal cancer.

J. Bendell, J. Infante, L. Fecher, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Safety and early efficacy results from a phase 1, multicenter trial of PSMA-targeted armored CAR T cells in patients with advanced mCRPC.

Jingsong Zhang, V. Narayan, M. Schweizer, 2022, Journal of Clinical Oncology.

613 Pharmacokinetics/pharmacodynamics (PK/PD) of GSK2256098, a Focal Adhesion Kinase (FAK) Inhibitor, in Patients with Advanced Solid Tumors

R. Plummer, M. Ranson, J. Soria, 2012 .

610 Loss of the Tumor Suppressor Merlin as a Potential Predictive Biomarker of Clinical Activity for the Oral, Focal Adhesion Kinase (FAK) Inhibitor GSK2256098 in Pts with Recurrent Mesothelioma

R. Plummer, M. Ranson, J. Soria, 2012 .